{
    "clinical_study": {
        "@rank": "9909", 
        "acronym": "HIJAK", 
        "arm_group": {
            "arm_group_label": "Ruxolitinib", 
            "arm_group_type": "Experimental", 
            "description": "Induction period: Ruxolitinib will be given twice daily during 6 cycles of 28 days.\nMaintenance period: patients who achieve at least a partial response at the end of cycle 6 will be eligible for maintenance treatment by ruxolitinib twice daily every day of 28-day cycles."
        }, 
        "brief_summary": {
            "textblock": "Phase II study to assess the efficacy of 6 cycles of oral JAK1/2 inhibitor ruxolitinib in\n      patients with advanced Hodgkin's lymphoma for whom no curative option is available."
        }, 
        "brief_title": "A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Hodgkin's Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Hodgkin Disease", 
                "Lymphoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion critera:\n\n          -  Patients \u2265 18 years with classical HL relapsing or refractory after at least 1 prior\n             systemic therapy. Patients must have relapsed after high-dose therapy with ASCT, or\n             have been deemed ineligible for high-dose therapy with ASCT\n\n          -  ECOG performance status \u2264 3\n\n          -  Measurable nodal disease: 1 cm in the longest transverse diameter and clearly\n             measurable in at least two perpendicular dimensions, as determined by CT scan (MRI is\n             allowed only if CT scan cannot be performed).\n\n          -  Patient has the following laboratory values:\n\n               -  Absolute neutrophil count (ANC) \u2265 1.0 x 10^9/L [SI units 1.0 x 10^9/L]\n\n               -  Platelet count \u2265 75 x 10^9/L]\n\n               -  Serum creatinine \u2264 1.5 x upper limit of normal (ULN)\n\n               -  Serum bilirubin \u2264 1.5 x ULN (or \u2264 3.0 x ULN, if patient has Gilbert syndrome)\n\n               -  AST/SGOT and/or ALT/SGPT \u2264 2.5 x ULN or \u2264 5.0 x ULN if the transaminase\n                  elevation is due to liver disease involvement\n\n          -  Signed written informed consent\n\n          -  Life expectancy \u2265 3 months\n\n          -  Corrected QT interval \u2264 450 mSec\n\n          -  Men and women of childbearing potential must agree to use an adequate method of\n             contraception during the study treatment and for at least 1 week after the last study\n             drug administration\n\n          -  The patient must be covered by a social security system (for inclusions in France)\n\n        Exclusion criteria:\n\n          -  Previous treatment with ruxolitinib or another JAK inhibitor\n\n          -  Contraindication to ruxolitinib\n\n          -  Patient received chemotherapy or radiotherapy or any investigational drug within 14\n             days prior to starting study drug or whose side effects of such therapy have not\n             resolved to \u2264 grade 1\n\n          -  Patient treated with allogeneic hematopoietic stem cell transplant who is currently\n             on, or has received immunosuppressive therapy within 90 days prior to start of\n             screening and/or have \u2265 Grade 2 graft versus host disease (GvHD).\n\n          -  Patient with prior history of another active primary malignancy \u2264 2 years before\n             study entry, with the exception of non-melanoma skin cancer, and carcinoma in situ of\n             uterine cervix\n\n          -  Any serious active disease or co-morbid medical condition that, according to the\n             investigator's decision, will substantially increase the risk associated with the\n             subject's participation in the study.\n\n          -  Uncontrolled infectious disease, including active HBV infection defined by either\n             detection of HBs Antigen or presence of anti HBc antibody without detectable anti HBs\n             antibody.\n\n          -  HIV, HCV or HTLV serology positivity and/or documented infection with active\n             hepatitis B\n\n          -  Prior history of CNS involvement with lymphoma\n\n          -  Pregnant or lactating woman\n\n          -  Adult patient unable to provide informed consent because of intellectual impairment,\n             any serious medical condition, laboratory abnormality or psychiatric illness."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "33", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01877005", 
            "org_study_id": "HIJAK"
        }, 
        "intervention": {
            "arm_group_label": "Ruxolitinib", 
            "intervention_name": "Ruxolitinib", 
            "intervention_type": "Drug", 
            "other_name": "JAKAVI"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Multicenter, single arm and opened label phase II study", 
        "lastchanged_date": "May 22, 2014", 
        "link": {
            "description": "LYSA (the Lymphoma Study Association)", 
            "url": "http://lysa-lymphoma.org"
        }, 
        "location": [
            {
                "contact": {
                    "email": "eric.vandenneste@uclouvain.be", 
                    "last_name": "Eric Van den Neste, MD", 
                    "phone": "32 2 7641875"
                }, 
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium", 
                        "zip": "10200"
                    }, 
                    "name": "UCL Louvain St Luc"
                }, 
                "investigator": [
                    {
                        "last_name": "Eric Van Den Neste, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Violaine Havelange, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Laurent Knoops, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Lucienne Michaux, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Xavier Poire, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Marie-Christine Vekemans, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Catherine Lambert, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "marc.andre@uclouvain.be", 
                    "last_name": "marc Andre, PhD", 
                    "phone": "32 81 423831"
                }, 
                "facility": {
                    "address": {
                        "city": "Yvoir", 
                        "country": "Belgium", 
                        "zip": "5530"
                    }, 
                    "name": "Universit\u00e9 Catholique de Louvain Mont Godinne"
                }, 
                "investigator": [
                    {
                        "last_name": "Marc Andre, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Anne Sonet, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Chantal Doyen, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Carlos Graux, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Christian Chatelain, PhD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "reman-o@chu-caen.fr", 
                    "last_name": "Oum\u00e9daly Reman, MD", 
                    "phone": "02 31 06 50 14"
                }, 
                "facility": {
                    "address": {
                        "city": "Caen", 
                        "country": "France", 
                        "zip": "14000"
                    }, 
                    "name": "Chu Cote de Nacre"
                }, 
                "investigator": [
                    {
                        "last_name": "Oum\u00e9daly REMAN, Doctor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "St\u00e9phane CHEZE, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Margaret MACRO, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Anne-Claire GAC, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Hyacinthe JOHNSON-ANSAH, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Khaled BENABED, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Sylvain CHANTEPIE, Doctor", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "corinne.haioun@hmn.aphp.fr", 
                    "last_name": "Corinne Haioun, PhD", 
                    "phone": "01 49 81 41 54"
                }, 
                "facility": {
                    "address": {
                        "city": "Creteil", 
                        "country": "France", 
                        "zip": "94010"
                    }, 
                    "name": "Hopital Henri Mondor"
                }, 
                "investigator": [
                    {
                        "last_name": "Karim BELHADJ-MERZOUG, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Corinne HAIOUN, Professor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Jehan DUPUIS, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Isabelle GAILLARD, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Fabien LE BRAS, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Catalina ENACHE, Doctor", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "olivier.casasnovas@chu-dijon.fr", 
                    "last_name": "Olivier Casasnovas, MD", 
                    "phone": "03 80 29 30 31"
                }, 
                "facility": {
                    "address": {
                        "city": "Dijon", 
                        "country": "France", 
                        "zip": "21000"
                    }, 
                    "name": "Chu Dijon"
                }, 
                "investigator": [
                    {
                        "last_name": "Olivier CASASNOVAS, Doctor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Jean-No\u00ebl BASTIE, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Denis CAILLOT, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Emmanuelle FERRANT, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Ingrid LAFON, Doctor", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "franck.morschhauser@chru-lille.fr", 
                    "last_name": "Franck Morschhauser, MD", 
                    "phone": "03 20 44 57 13"
                }, 
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France", 
                        "zip": "59037"
                    }, 
                    "name": "Chru de Lille"
                }, 
                "investigator": [
                    {
                        "last_name": "Franck MORSCHHAUSER, Doctor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Mathieu WEMEAU, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "B\u00e9n\u00e9dicte HIVERT, Doctor", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "catherine.sebban@lyon.unicancer.fr", 
                    "last_name": "Catherine Sebban, MD", 
                    "phone": "04 78 78 27 57"
                }, 
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France", 
                        "zip": "69373"
                    }, 
                    "name": "Centre Leon Berard"
                }, 
                "investigator": [
                    {
                        "last_name": "Catherine SEBBAN, Doctor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Pierre BIRON, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Herv\u00e9 GHESQUIERES, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Pierre FAURIE, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Amine BELHABRI, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Emmanuelle NICOLAS-VIRELIZIER, Doctor", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "gilles.salles@chu-lyon.fr", 
                    "last_name": "Gilles Salles, PhD", 
                    "phone": "04 78 86 43 01"
                }, 
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France", 
                        "zip": "69495"
                    }, 
                    "name": "Centre Hospitalier Lyon Sud"
                }, 
                "investigator": [
                    {
                        "last_name": "Gilles SALLES, Professor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Bertrand COIFFIER, Professor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Fadhela BOUAFIA-SAUVY, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Laure LEBRAS, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Daniel ESPINOUSE, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Lionel KARLIN, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Anne-Sophie MICHALLET, Doctor", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "steven.legouill@chu-nantes.fr", 
                    "last_name": "Steven Le Gouill, PhD", 
                    "phone": "02 40 08 32 71"
                }, 
                "facility": {
                    "address": {
                        "city": "Nantes", 
                        "country": "France", 
                        "zip": "44093"
                    }, 
                    "name": "CHU de Nantes, Hotel Dieu"
                }, 
                "investigator": [
                    {
                        "last_name": "Thomas GASTINNE, Doctor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Nicolas BLIN, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "B\u00e9atrice MAHE, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Cyrille TOUZEAU, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Karine AUGEUL-MEUNIER, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Steven LE GOUILL, Professor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Viviane DUBRUILLE, Doctor", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "herve.tilly@chb.unicancer.fr", 
                    "last_name": "Herv\u00e9 Tilly, PhD", 
                    "phone": "02 32 08 22 02"
                }, 
                "facility": {
                    "address": {
                        "city": "Rouen", 
                        "country": "France", 
                        "zip": "76038"
                    }, 
                    "name": "Centre Henri Becquerel"
                }, 
                "investigator": [
                    {
                        "last_name": "Aspasia STAMATOULLAS, Doctor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Fabrice JARDIN, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Herv\u00e9 TILLY, Professor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "St\u00e9phane LEPRETRE, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Pascal LENAIN, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Nathalie CONTENTIN, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Emilie LEMASLE, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "H\u00e9l\u00e8ne LANIC, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Nathalie CARDINAEL, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Marie-Laure FONTOURA, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Carole FRONVILLE, Doctor", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "France"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma", 
        "overall_contact": {
            "email": "anastassia.traore@lysarc.org", 
            "last_name": "Anastassia TRAORE", 
            "phone": "+33472244174"
        }, 
        "overall_contact_backup": {
            "email": "elise.hutasse@lysarc.org", 
            "last_name": "Elise HUTASSE", 
            "phone": "+33472244177"
        }, 
        "overall_official": [
            {
                "affiliation": "Lymphoma Study Association", 
                "last_name": "Eric Van Den Neste, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Lymphoma Study Association", 
                "last_name": "Franck Morschhauser, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Overall Response Rate according to the International Working Group critera (Cheson 2007) is defined as patient with Complete response or Partial response.\nPatient without response assessment (due to whatever reason) will be considered as non responder.", 
            "measure": "Overall response Rate (ORR) according to Cheson 2007", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01877005"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall Response Rate according to the International Working Group critera (Cheson 1999) is defined as patient with Complete response, unconfirmed Complete response or Partial response.\nPatient without response assessment (due to whatever reason) will be considered as non responder.", 
                "measure": "Overall response rate (ORR) according to Cheson 1999", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Assessment of response will be based on the International Workshop to Standardize Response criteria for lymphoma: Cheson, 1999 and 2007.\nPatient without response assessment (due to whatever reason) will be considered as nonresponder.", 
                "measure": "Complete response rates (CR) according to Cheson 2007 and 1999", 
                "safety_issue": "No", 
                "time_frame": "2 months, 4 months and 6 months"
            }, 
            {
                "description": "Disease response evaluation at 2; 4 and 6 months will be used to determine the Best Response Rate, according to Cheson 1999 and 2007.\nThe Best Complete Response and Best Overall Response will be presented. Patient without response assessment (due to whatever reason) will be considered as nonresponder.", 
                "measure": "Best Response Rate (BRR) according to Cheson 1999 and 2007", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Description of all adverse events, vital signs measurements, clinical laboratory measurements and concomitant medications.", 
                "measure": "Safety endpoints", 
                "safety_issue": "Yes", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Time to response will be defined as the time from inclusion into the study to the time of attainment of PR or CR according to Cheson 2007 criteria.", 
                "measure": "Time to response", 
                "safety_issue": "No", 
                "time_frame": "Up to 30 months"
            }, 
            {
                "description": "Duration of response will be measured from the time of attainment of CR or PR according to Cheson 2007 cirteria to the date of first documented disease progression, relapse or death from any cause.\nPatients alive and free of progression will be censored at their last follow-up date.", 
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "Up to 4.5 years"
            }, 
            {
                "description": "PFS is defined at the time from inclusion into the study to the first observation of documented disease progression/relapse according to Cheson 2007 criteria or death due to any cause.\nIf a subject has not progressed or died, PFS will be censored at the time of last visit.", 
                "measure": "Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 4.5 years"
            }, 
            {
                "description": "OS will be measured from the date of inclusion to the date of death from any cause.\nPatients who did not died will be censored at the time of last visit.", 
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 4.5 years"
            }, 
            {
                "description": "Evaluation of efficacy of ruxolitinib on systemic symptoms such as fever, sweating, fatigue  and itching  will be done via systemic symptoms Questionnaire designed for this purpose and completed at Baseline and then at Day1 of each visit during Induction and Maintenance period of the study", 
                "measure": "Evaluation of systemic symptoms", 
                "safety_issue": "No", 
                "time_frame": "Up to 30 months"
            }
        ], 
        "source": "The Lymphoma Academic Research Organisation", 
        "sponsors": {
            "collaborator": {
                "agency": "Novartis", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "The Lymphoma Academic Research Organisation", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}